Eleison's mission is to acquire,develop,and commercialize clinical stage drug candidates for "orphan" cancers,providing new hope for patients with rare,life-threatening diseases.

1. ELEISON RECENT NEWS
May 6, 2014 - Mr. Timothy Whitten Joins Eleison Pharmaceuticals Board of Directors
January 3, 2014 - Eleison Announces Achievement of Enrollment Milestone in its Phase II Trial
of ILC for Pediatric Bone Cancer
October 8, 2013 - ILC Granted Orphan Drug Designation in Europe for the Treatment of
Osteosarcoma
SITEMAP RESOURCES
Eleison Pharmaceuticals, LLC.
Osteosarcoma Clinical Trials Slideshow
Osteosarcoma Clinical Trials Video
About Eleison Pharmaceuticals
Company News
Career Opportunities
Contact